β-Lactamases identified in clinical isolates of Pseudomonas aeruginosa

Critical Reviews in Microbiology

Volumn 36, Issue 3, 2010, Pages 245-258

  Zhao, Wei Hua ^a   Hu, Zhi Qing ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

lactamases; Nosocomial infection; Pseudomonas aeruginosa

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE CTX M; BETA LACTAMASE SHV; BETA LACTAMASE TEM 1; BIAPENEM; CARBAPENEMASE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CLAVULANIC ACID; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GUIANA EXTENDED SPECTRUM BETA LACTAMASE 1; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; PANIPENEM; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIMENTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIETNAMESE EXTENDED SPECTRUM BETA LACTAMASE 1; BACTERIAL PROTEIN; BETA LACTAM;

ACINETOBACTER; AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG ACTIVITY; ENZYME ACTIVITY; GRAM NEGATIVE BACTERIUM; HYDROLYSIS; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; UNINDEXED SEQUENCE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MICROBIOLOGY; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ACINETOBACTER; BACILLI (CLASS); NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 77954718693     PISSN: 1040841X     EISSN: 15497828     Source Type: Journal    
DOI: 10.3109/1040841X.2010.481763     Document Type: Review

References (143)

1. Al Naiemi N, Duim B, Bart A. (2006). A CTX-M extended-spectrum β-lactamase in Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J Med Microbiol 55, 1607-1608.
2. Alibert-Franco S, Pradines B, Mahamoud A, Davin-Regli A, Pagès JM. (2009). Efux mechanism, an attractive target to combat multid-rug resistant Plasmodium falciparum and Pseudomonas aerugi-nosa. Curr Med Chem 16, 301-317.
3. Ambler RP. (1980). Te structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 289, 321-331.
4. Andrade SS, Jones RN, Gales AC, Sader HS. (2003). Increasing prevalence of antimicrobial resistance among Pseudomonas aerugi-nosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). J Antimicrob Chemother 52, 140-141.
5. Aubert D, Poirel L, Ali AB, Goldstein FW, Nordmann P. (2001a). OXA-35 is an OXA-10-related β-lactamase from Pseudomonas aeruginosa. J Antimicrob Chemother 48, 717-721.
6. Aubert D, Poirel L, Chevalier J, Leotard S, Pages JM, Nordmann P. (2001b). Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa. Antimicrob Agents Chemother 45, 1615-1620.
7. Bahar G, Mazzariol A, Koncan R, Mert A, Fontana R, Rossolini GM, Cornaglia G. (2004). Detection of VIM-5 metallo-β-lactamase in a Pseudomonas aeruginosa clinical isolate from Turkey. J Antimicrob Chemother 54, 282-283.
8. Bassetti M, Nicolini L, Esposito S, Righi E, Viscoli C. (2009). Current status of newer carbapenems. Curr Med Chem 16, 564-575.
9. PER-2, which encodes an extended-spectrum class A β-lactamase. Antimicrob Agents Chemother 40, 616-620.
10. Bonomo RA, Szabo D. (2006). Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 43, S49-56.
11. Bradford PA. (2001). Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, detection of this important resistance threat. Clin Microbiol Rev 14, 933-951.
12. Burman LG, Park JT, Lindström EB, Boman HG. (1973). Resistance of Escherichia coli to penicillins: identifcation of the structural gene for the chromosomal penicillinase. J Bacteriol 116, 123-130.
13. Bush K. (1988). β-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev 1, 109-123.
14. Bush K, Jacoby GA, Medeiros AA. (1995). A functional classifcation scheme for β-lactamases and its correlation with molecular structures. Antimicrob Agents Chemother 39, 1211-1233.
15. Bush K, Jacoby GA. (2010). Updated functional classifcation of β-lactamases. Antimicrob Agents Chemother 54, 969-976.
16. Cagnacci S, Gualco L, Roveta S, Mannelli S, Borgianni L, Docquier JD, Dodi F, Centanaro M, Debbia E, Marchese A, Rossolini GM. (2008). Bloodstream infections caused by multid-rug-resistant Klebsiella pneumoniae producing the carbapenem-hydrolysing VIM-1 metallo-β-lactamase: frst Italian outbreak. J Antimicrob Chemother 61, 296-300.
17. Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN. (2009). Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-b-lactamase clones (VIM-2,-5,-6, and-11 and the newly characterized VIM-18). Antimicrob Agents Chemother 53, 1225-1227.
18. GIM-1, encoding a new subclass of metallo-β-lactamase. Antimicrob Agents Chemother 48, 4654-4661.
19. PER-2 β-lactamase genes in clinical isolates from Bolivian hospitals. J Antimicrob Chemother 57, 975-978.
20. Chanawong A, M'Zali FH, Heritage J, Lulitanond A, Hawkey PM. (2001). SHV-12, SHV-5, SHV-2a and VEB-1 extended-spectrum β-lactamases in gram-negative bacteria isolated in a university hospital in Tailand. J Antimicrob Chemother 48, 839-852.
21. Chaïbi EB, Sirot D, Paul G, Labia R. (1999). Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 43, 447-458.
22. Couture F, Lachapelle J, Levesque RC. (1992). Phylogeny of LCR-1 and OXA-5 with class A and class D β-lactamases. Mol Microbiol 6, 1693-1705.
23. Crespo MP, Woodford N, Sinclair A, Kaufmann ME, Turton J, Glover J, Velez JD, Castaneda CR, Recalde M, Livermore DM. (2004). Outbreak of carbapenem-resistant Pseudomonas aeru-ginosa producing VIM-8, a novel metallo-β-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 42, 5094-5101.
24. Danel F, Hall LM, Duke B Gur D, Livermore DM. (1999). OXA-17, a further extended-spectrum variant of OXA-10 β-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother 43, 1362-1366.
25. Danel F, Hall LM, Gur D, Livermore DM. (1995). OXA-14, another extended-spectrum variant of OXA-10. (PSE-2). β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 39, 1881-1884.
26. Danel F, Hall LM, Gur D, Livermore DM. (1997). OXA-15, an extended-spectrum variant of OXA-2 β-lactamase, isolated from a Pseudomonas aeruginosa strain. Antimicrob Agents Chemother 41, 785-790.
27. Danel F, Hall LM, Gur D, Livermore DM. (1998). OXA-16, a further extended-spectrum variant of OXA-10 β-lactamase, from two Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother 42, 3117-3122.
28. Datta N, Kontomichalou P. (1965). Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature 208, 239-241.
29. Drawz SM, Bonomo RA. (2010). Tree decades of β-lactamase inhibitors. Clin Microbiol Rev 23, 160-201.
30. TEM-21 gene located on a chromosomal interrupted TnA type transposon. Antimicrob Agents Chemother 46, 3624-3626.
31. GES-1 and a fused product of aac3-Ib/aac6′-Ib' gene cassettes in Pseudomonas aeruginosa Antimicrob. Agents Chemother 46, 638-645.
32. Duljasz W, Gniadkowski M, Sitter S, Wojna A, Jebelean C. (2009). First organisms with acquired metallo-β-lactamases. (IMP-13, IMP-22, VIM-2). reported in Austria. Antimicrob Agents Chemother 53, 2221-2222.
33. Empel J, Filczak K, Mrówka A, Hryniewicz W, Livermore DM, Gniadkowski M. (2007). Outbreak of Pseudomonas aerugi-nosa infections with PER-1 extended-spectrum β-lactamase in Warsaw, Poland: further evidence for an international clonal complex. J Clin Microbiol 45, 2829-2834.
34. VIM-1 and aac(6′)-IIc in an Enterobacter cloacae clinical isolate from Greece. J Antimicrob Chemother 55, 634-638.
35. Gales AC, Menezes LC, Silbert S, Sader HS. (2003). Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase. J Antimicrob Chemother 52, 699-702.
36. IMP-15 in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. Antimicrob Agents Chemother 52, 2943-2946.
37. IMP-7. Antimicrob Agents Chemother 46, 255-258.
38. Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA. (2005). Te Sanford Guide to Antimicrobial Terapy 2005, 35th ed. Hyde Park, VT: Antimicrobial Terapy.
39. Girlich D, Naas T, Leelaporn A, Poirel L, Fennewald M, Nordmann P. (2002). Nosocomial spread of the integron-located veb-1-like cassette encoding an extended-spectrum β-lactamase in Pseudomonas aeruginosa in Tailand. Clin Infect Dis 34, 603-611.
40. Girlich D, Naas T, Nordmann P. (2004). Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob Agents Chemother 48, 2043-2048.
41. VIM-1-containing integron from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 49, 1973-1980.
42. Giwercman B, Lambert PA, Rosdahl VT, Shand GH, Høiby N. (1990). Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fbrosis patients due to in-vivo selection of stable partially derepressed β-lactamase producing strains. J Antimicrob Chemother 26, 247-259.
43. Hall LM, Livermore DM, Gur D, Akova M, Akalin HE. (1993). OXA-11, an extended-spectrum variant of OXA-10. (PSE-2). β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 37, 1637-1644.
44. Hanson ND, Hossain A, Buck L, Moland ES, Tomson KS. (2006). First occurrence of a Pseudomonas aeruginosa isolate in the United States producing an IMP metallo-β-lactamase, IMP-18. Antimicrob Agents Chemother 50, 2272-2273.
45. IMP-4 at a 320-bed tertiary hospital in Australia. Infect Control Hosp Epidemiol 28, 98-101.
46. IMP-10 in clinical isolates of Serratia marcescens. J Med Microbiol 58, 217-221.
47. Iyobe S, Kusadokoro H, Takahashi A, Yomoda S, Okubo T, Nakamura A, O'Hara K. (2002). Detection of a variant metallo-β-lactamase, IMP-10, from two unrelated strains of Pseudomonas aerugi-nosa and an Alcaligenes xylosoxidans strain. Antimicrob Agents Chemother 46, 2014-2016.
48. Jacoby GA. (2009). AmpC β-lactamases. Clin Microbiol Rev 22, 161-182.
49. Jacoby GA, Matthew M. (1979). Te distribution of β-lactamase genes on plasmids found in Pseudomonas. Plasmid 2, 41-47.
50. Juan C, Beceiro A, Gutiérrez O, Albertí S, Garau M, Pérez JL, Bou G, Oliver A. (2008). Characterization of the new metallo-β-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeru-ginosa clinical isolate in Spain. Antimicrob Agents Chemother 52, 3589-3596.
51. Juan C, Mulet X, Zamorano L, Albertí S, Pérez JL, Oliver A. (2009). Detection of the novel extended-spectrum β-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. Antimicrob Agents Chemother 53, 5288-5290.
52. Kliebe C, Nies BA, Meyer JF, Tolxdorf-Neutzling RM, Wiedemann B. (1985). Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother 28, 302-307.
53. Kong KF, Jayawardena SR, Del Puerto A, Wiehlmann L, Laabs U, Tümmler B, Mathee K. (2005). Characterization of poxB, a chromosomal-encoded Pseudomonas aeruginosa oxacillinase. Gene 358, 82-92.
54. CARB-3 gene encoding the carbenicillinase-3 β-lactamase of Pseudomonas aeruginosa. Gene 102, 7-12.
55. VIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 43, 1584-1590.
56. Lister PD. (2000). β-Lactamase inhibitor combinations with extended-spectrum penicillins: factors infuencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa. Pharmacotherapy 20, 213S-218S.
57. Lister PD. (2002). Chromosomally-encoded resistance mechanisms of Pseudomonas aeruginosa: therapeutic implications. Am J Pharmacogenomics 2, 235-243.
58. Lister PD. (2007). Carbapenems in the USA: focus on doripenem. Expert Rev Anti Infect Ter 5, 793-809.
59. Livermore DM. (1995). β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8, 557-584.
60. Lodge JM, Minchin SD, Piddock LJ, Busby SJ. (1990). Cloning, sequencing and analysis of the structural gene and regulatory region of the Pseudomonas aeruginosa chromosomal ampC β-lactamase. Biochem J 272, 627-631.
61. Lombardi G, Luzzaro F, Docquier JD, Riccio ML, Perilli M, Colì A, Amicosante G, Rossolini GM, Toniolo A. (2002). Nosocomial infections caused by multidrug-resistant isolates of Pseudomonas putida producing VIM-1 metallo-β-lactamase. J Clin Microbiol 40, 4051-4055.
62. Marchandin H, Jean-Pierre H, De Champs C, Sirot D, Darbas H, Perigault PF, Carriere C. (2000). Production of a TEM-24 plasmid-mediated extended-spectrum β-lactamase by a clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother 44, 213-216.
63. Matthew M, Hedges RW, Smith JT. (1979). Types of β-lactamase determined by plasmids in gram-negative bacteria. J Bacteriol 138, 657-662.
64. Mavroidi A, Tzelepi E, Tsakris A, Miriagou V, Sofanou D, Tzouvelekis LS. (2001). An integron-associated β-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum β-lactamase IBC-1. J Antimicrob Chemother 48, 627-630.
65. Mazel D. (2006). Integrons: agents of bacterial evolution. Nat Rev Microbiol 4, 608-620.
66. IMP-16, a fused form of aminoglycoside-resistant gene aac(6′)-30/aac(6′)-Ib': report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 48, 4693-4702.
67. Mitsuhashi S, Inoue M. (1981). Mechanisms of resistance to β-lactam antibiotics, In S Mitsuhashi. (ed), Beta-lactam antibiotics. Springer-Verlag, New York, pp. 41-56.
68. Mugnier P, Casin I, Bouthors AT, Collatz E. (1998a). Novel OXA-10-derived extended-spectrum β-lactamases selected in vivo or in vitro. Antimicrob Agents Chemother 42, 3113-3116.
69. Mugnier P, Dubrous P, Casin I, Arlet G, Collatz E. (1996). A TEM-derived extended-spectrum β-lactamase in Pseudomonas aeru-ginosa. Antimicrob Agents Chemother 40, 2488-2493.
70. Mugnier P, Podglajen I, Goldstein FW, Collatz E. (1998b). Carbapenems as inhibitors of OXA-13, a novel, integron-encoded β-lactamase in Pseudomonas aeruginosa. Microbiology 144, 1021-1031.
71. Naas T, Philippon L, Poirel L, Ronco E, Nordmann P. (1999a). An SHV-derived extended-spectrum β-lactamase in Pseudomonas aerugi-nosa. Antimicrob Agents Chemother 43, 1281-1284.
72. Naas T, Poirel L, Karim A, Nordmann P. (1999b). Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum β-lactamase VEB-1 in Pseudomonas aerugi-nosa. FEMS Microbiol Lett 176, 411-419.
73. Naas T, Sougakof W, Casetta A, Nordmann P. (1998). Molecular characterization of OXA-20, a novel class D β-lactamase, its integron from Pseudomonas aeruginosa. Antimicrob Agents Chemother 42, 2074-2083.
74. Naas T, Nordmann P. (1999). OXA-type β-lactamases. Curr Pharm Des 5, 865-879.
75. Naiemi NA, Duim B, Savelkoul PH, Spanjaard L, de Jonge E, Bart A, Vandenbroucke-Grauls CM, de Jong MD. (2005). Widespread transfer of resistance genes between bacterial species in an intensive care unit: implications for hospital epidemiology. J Clin Microbiol 43, 4862-4864.
76. Nordmann P, Cuzon G, Naas T. (2009). Te real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9, 228-236.
77. Nordmann P, Ronco E, Naas T, Duport C, Michel-Briand Y, Labia R. (1993). Characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 37, 962-969.
78. Nordmann P, Guibert M. (1998). Extended-spectrum β-lactamases in Pseudomonas aeruginosa. J Antimicrob Chemother 42, 128-132.
79. Obritsch MD, Fish DN, MacLaren R, Jung R. (2005). Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25, 1353-1364.
80. Osano E, Arakawa Y, Wacharotayankun R, Ohta M, Horii T, Ito H, Yoshimura F, Kato N. (1994). Molecular characterization of an enterobacterial metallo β-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother 38, 71-78.
81. VIM family in a GES-1 extended-spectrum-β-lactamase-producing Pseudomonas aeruginosa clinical isolate in Argentina. Antimicrob Agents Chemother 49, 474-475.
82. Paterson DL, Bonomo RA. (2005). Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 18, 657-686.
83. Petroni A, Melano RG, Saka HA, Garutti A, Mange L, Pasterán F, Rapoport M, Miranda M, Faccone D, Rossi A, Hofman PS, Galas MF. (2004). CARB-9, a carbenicillinase encoded in the VCR region of Vibrio cholerae non-O1, non-O139 belongs to a family of cassette-encoded β-lactamases. Antimicrob Agents Chemother 48, 4042-4046.
84. Philippon AM, Paul GC, Jacoby GA. (1983). Properties of PSE-2 β-lactamase and genetic basis for its production in Pseudomonas aeruginosa. Antimicrob Agents Chemother 24, 362-369.
85. Philippon AM, Paul GC, Jacoby GA. (1986). New plasmid-mediated oxacillin-hydrolyzing β-lactamase in Pseudomonas aeruginosa. J Antimicrob Chemother 17, 415-422.
86. Philippon LN, Naas T, Bouthors AT, Barakett V, Nordmann P. (1997). OXA-18, a class D clavulanic acid-inhibited extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 41, 2188-2195.
87. Picão RC, Poirel L, Gales AC, Nordmann P. (2009). Further identifca-tion of CTX-M-2 extended-spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53, 2225-2226.
88. Poirel L, Brinas L, Fortineau N, Nordmann P. (2005a). Integron-encoded GES-type extended-spectrum β-lactamase with increased activity toward aztreonam in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49, 3593-3597.
89. Poirel L, Brinas L, Verlinde A, Ide L, Nordmann P. (2005b). BEL-1, a novel clavulanic acid-inhibited extended-spectrum β-lactamase, the class 1 integron In120 in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49, 3743-3748.
90. Poirel L, Gerome P, De Champs C, Stephanazzi J, Naas T, Nordmann P. (2002a). Integron-located oxa-32 gene cassette encoding an extended-spectrum variant of OXA-2 β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 46, 566-569.
91. Poirel L, Girlich D, Naas T, Nordmann P. (2001a). OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aer-uginosa and its plasmid-and integron-located gene. Antimicrob Agents Chemother 45, 447-453.
92. Poirel L, Le Tomas I, Naas T, Karim A, Nordmann P. (2000a). Biochemical sequence analyses of GES-1, a novel class A extended-spectrum β-lactamase, the class 1 integron In52 from Klebsiella pneumonia. Antimicrob Agents Chemother 44, 622-632.
93. Poirel L, Lebessi E, Castro M, Fèvre C, Foustoukou M, Nordmann P. (2004a). Nosocomial outbreak of extended-spectrum β-lactamase SHV-5-producing isolates of Pseudomonas aeruginosa in Athens, Greece. Antimicrob Agents Chemother 48, 2277-2279.
94. SPM-1-surrounding sequences from disseminated Pseudomonas aeruginosa isolates in Recife, Brazil. Antimicrob Agents Chemother 48, 1406-1409.
95. Poirel L, Naas T, Guibert M, Chaibi EB, Labia R, Nordmann P. (1999a). Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum β-lactamase encoded by an Escherichia coli integron gene. Antimicrob Agents Chemother 43, 573-581.
96. Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo JD, Nordmann P. (2000b). Characterization of VIM-2, a carbapenem-hydrolyz-ing metallo-β-lactamase and its plasmid-and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 44, 891-897.
97. Poirel, L, Naas, T, Nordmann, P. (2010). Diversity, epidemiology, genetics of class D beta-lactamases. Antimicrob Agents Chemother 54, 24-38.
98. Poirel L, Ronco E, Naas T, Nordmann P. (1999b). Extended-spectrum β-lactamase TEM-4 in Pseudomonas aeruginosa. Clin Microbiol Infect 5, 651-652.
99. Poirel L, Rotimi VO, Mokaddas EM, Karim A, Nordmann P. (2001b). VEB-1-like extended-spectrum β-lactamases in Pseudomonas aeruginosa, Kuwait. Emerg Infect Dis 7, 468-470.
100. Poirel L, Weldhagen G F, De Champs C, Nordmann P. (2002b). A noso-comial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum β-lactamase GES-2 in South Africa. J Antimicrob Chemother 49, 561-565.
101. Poirel L, Weldhagen GF, Naas T, De Champs C, Dove MG, Nordmann P. (2001c). GES-2, a class A β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob Agents Chemother 45, 2598-2603.
102. VIM-1 in a clinical strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother 46, 4026-4028.
103. Queenan AM, Bush K. (2007). Carbapenemases, the versatile β-lactamases. Clin Microbiol Rev 20, 440-458.
104. Rasmussen BA, Bush K. (1997). Carbapenem-hydrolyzing β-lactamases. Antimicrob Agents Chemother 41, 223-232.
105. VIM-1-containing integron carrying a new aminoglycoside phosphotransferase gene cassette. Antimicrob Agents Chemother 45, 1249-1253.
106. Rodríguez-Martínez JM, Poirel L, Nordmann P. (2009). Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53, 1766-1771.
107. Rossolini GM, Luzzaro F, Migliavacca R, Mugnaioli C, Pini B, De Luca F, Perilli M, Pollini S, Spalla M, Amicosante G, Toniolo A, Pagani L. (2008). First countrywide survey of acquired metallo-β-lactamases in gram-negative pathogens in Italy. Antimicrob Agents Chemother 52, 4023-4029.
108. Ryoo NH, Lee K, Lim JB, Lee YH, Bae IK, Jeong SH. (2009). Outbreak by meropenem-resistant Pseudomonas aeruginosa producing IMP-6 metallo-β- lactamase in a Korean hospital. Diagn Microbiol Infect Dis 63, 115-117.
109. Sader HS, Reis AO, Silbert S, Gales AC. (2005). IMPs, VIMs and SPMs, the diversity of metallo-β-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in a Brazilian hospital. Clin Microbiol Infect 11, 73-76.
110. Sanschagrin F, Bejaoui N, Levesque RC. (1998). Structure of CARB-4 and AER-1 carbenicillin-hydrolyzing β-lactamases. Antimicrob Agents Chemother 42, 1966-1972.
111. Schneider I, Keuleyan E, Rasshofer R, Markovska R, Queenan AM, Bauernfeind A. (2008). VIM-15 and VIM-16, two new VIM-2-like metallo-β-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. Antimicrob Agents Chemother 52, 2977-2979.
112. VIM-1 metallo-β- lactamase gene. Diagn Microbiol Infect Dis 48, 167-172.
113. Shahid M, Sobia F, Singh A, Malik A, Khan HM, Jonas D, Hawkey PM. (2009). β-lactams and β-lactamase-inhibitors in current-or potential-clinical practice, a comprehensive update. Crit Rev Microbiol 35, 81-108.
114. Shibata N, Doi Y, Yamane K, Yagi T, Kurokawa H, Shibayama K, Kato H, Kai K, Arakawa Y. (2003). PCR typing of genetic determinants for metallo-β-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J Clin Microbiol 41, 5407-5413.
115. VIM-17 metallo-β-lactamase gene. Antimicrob Agents Chemother 53, 1325-1330.
116. Stokes HW, Hall RM.(1989). A novel family of potentially mobile DNA elements encoding site-specifc gene-integration functions, inte-grons. Mol Microbiol 3, 1669-1683.
117. Tam VH, Schilling AN, LaRocco MT, Gentry LO, Lolans K, Quinn JP, Garey KW. (2007). Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 13, 413-418.
118. Tassios PT, Gennimata V, Spaliara-Kalogeropoulou L, Kairis D, Koutsia C, Vatopoulos AC, Legakis NJ. (1997). Multiresistant Pseudomonas aeruginosa serogroup O,11 outbreak in an intensive care unit. Clin Microbiol Infect 3, 621-628.
119. IMP-13, harboured by a novel Tn5051-type transposon disseminating carbapenemase genes in Europe, report from the SENTRY worldwide antimicrobial surveillance programme. J Antimicrob Chemother 52, 583-590.
120. Toleman MA, Rolston K, Jones RN, Walsh TR. (2003b). Molecular and biochemical characterization of OXA-45, an extended-spectrum class 2d' β-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 47, 2859-2863.
121. VIM-7, an evo-lutionarily distinct metallo-β-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother 48, 329-332.
122. Toleman MA, Simm AM, Murphy TA, Gales AC, Biedenbach DJ, Jones RN, Walsh TR. (2002). Molecular characterization of SPM-1, a novel metallo-β- lactamase isolated in Latin America, report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother 50, 673-679.
123. Tsakris A, Ikonomidis A, Pournaras S, Tzouvelekis LS, Sofanou D, Legakis NJ, Maniatis AN. (2006). VIM-1 metallo-β-lactamase in Acinetobacter baumannii. Emerg Infect Dis 12, 981-983.
124. Tzouvelekis LS, Bonomo RA. (1999). SHV-type β-lactamases. Curr Pharm Des 5, 847-864.
125. Vahaboglu H, Oztürk R, Aygün G, Cokunkan F, Yaman A, Kaygusuz A, Leblebicioglu H, Balik I, Aydin K, Otkun M. (1997). Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey, a nationwide multicenter study. Antimicrob Agents Chemother 41, 2265-2269.
126. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP, Colombian Nosocomial Resistance Study Group. (2007). First identifcation of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lactamase. Antimicrob Agents Chemother 51, 1553-1555.
127. Vourli S, Tsorlini H, Katsifa H, Polemis M, Tzouvelekis LS, Kontodimou A, Vatopoulos AC. (2006). Emergence of Proteus mirabilis carrying the bla metallo-β-lactamase gene. Clin Microbiol Infect 12, 691-694.
128. Waley SG. (1992). β-Lactamase, mechanism of action, p 198-228 In M I Page. (ed), Te chemistry of β-lactams. Chapman and Hall, London.
129. Walsh TR, Toleman MA, Poirel L, Nordmann P. (2005). Metallo-β- lactamases, the quiet before the storm? Clin Microbiol Rev 18, 306-325.
130. Walther-Rasmussen J, Høiby N. (2007). Class A carbapenemases. J Antimicrob Chemother 60, 470-482.
131. Wang C, Cai P, Chang D, Mi Z. (2006). A Pseudomonas aeruginosa isolate producing the GES-5 extended-spectrum β-lactamase. J Antimicrob Chemother 57, 1261-1262.
132. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. (1991). Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 35, 147-151.
133. Weile J, Rahmig H, Gfröer S, Schroeppel K, Knabbe C, Susa M. (2007). First detection of a VIM-1 metallo-β-lactamase in a carbapenem-resistant Citrobacter freundii clinical isolate in an acute hospital in Germany. Scand J Infect Dis 39, 264-266.
134. Weldhagen GF, Poirel L, Nordmann P. (2003). Ambler class A extended-spectrum β-lactamases in Pseudomonas aeruginosa, novel developments and clinical impact. Antimicrob Agents Chemother 47, 2385-2392.
135. Wisplinghof H, Bischof T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. (2004). Nosocomial bloodstream infections in US hospitals, analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39, 309-317.
136. Wolter DJ, Kurpiel PM, Woodford N, Palepou MF, Goering RV, Hanson ND. (2009). Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. Antimicrob Agents Chemother 53, 557-562.
137. Woodford N, Zhang J, Kaufmann ME, Yarde S, Tomas Mdel M, Faris C, Vardhan MS, Dawson S, Cotterill SL, Livermore DM. (2008). Detection of Pseudomonas aeruginosa isolates producing VEB-type extended-spectrum β-lactamases in the United Kingdom. J Antimicrob Chemother 62, 1265-1268.
138. IMP-9 and its association with large plasmids carried by Pseudomonas aeru-ginosa isolates from the People's Republic of China. Antimicrob Agents Chemother 50, 355-358.
139. Yan JJ, Hsueh PR, Ko WC, Luh KT, Tsai SH, Wu HM, Wu JJ. (2001). Metallo-β-lactamases in clinical Pseudomonas isolates in Taiwan and identifcation of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother 45, 2224-2228.
140. Yan JJ, Hsueh PR, Lu JJ, Chang FY, Ko WC, Wu JJ. (2006). Characterization of acquired β-lactamases and their genetic support in multidrug-resistant Pseudomonas aeruginosa isolates in Taiwan, the prevalence of unusual integrons. J Antimicrob Chemother 58, 530-536.
141. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC. (2001). Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapen-em-resistant strain of Klebsiella pneumonia. Antimicrob Agents Chemother 45, 1151-1161.
142. Yoshimura F, Nikaido H. (1982). Permeability of Pseudomonas aeru-ginosa outer membrane to hydrophilic solutes. J Bacteriol 152, 636-642.
143. VIM-2 in clinical isolates of Pseudomonas aeruginosa. J Med Microbiol 58, 1080-1085.